market uncertainty

Ted Driscoll’s WSJ interview: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says

By Claremont Creek Alerts / December 16, 2013 / 0 Comments

source:   by Timothy Hay When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes. But it was more of […]

Read More

Entrepreneurs: The End Is Near. Refinance.

By John Steuart / September 28, 2011 / 0 Comments

September 28, 2011  source: Wall Street Journal All good things, unfortunately, come to an end. The last year or two have been spectacular for entrepreneurs. Investor enthusiasm has been intense, meaning that start-ups had the upper hand and could get financing at extraordinarily generous terms. But I’m afraid that the curtain is about to fall. […]

Read More

Goldhaber claims there’s still plenty of investor enthusiasm for companies that are installing or financing solar projects

By Claremont Creek Alerts / September 25, 2011 / 0 Comments

September  23, 2011  source: Forbes What the Solyndra Bankruptcy Means for Cleantech Investors by Jennifer Kho. Forbes Contributor As executives of defunct solar-panel manufacturer Solyndra keep mum in Washington, Silicon Valley and Wall Street are discussing what the bankruptcy – and the federal investigation – could mean for investors. “It has an impact; it’s such a […]

Read More

IPOs look dicey, but private equity may pick up some of the slack

By Claremont Creek Alerts / September 15, 2011 / 0 Comments

September 15, 2011  source: Xconomy For a while, I was optimistic that 2011 would be a good year for venture capital-backed IPOs, and it wasn’t just wishful thinking. There were 72 VC-backed IPOs last year—six times as many as in 2009. The year ended with a bang and 2011 got off to a good start. […]

Read More

Will the Stem Cell Ruling Affect Venture Capital Investing?

By Brad Webb / September 1, 2010 / 0 Comments

September 1, 2010 source: xconomy Brad Webb, Venture Partner at Claremont Creek Ventures, was featured today on the xcononomy website discussing the implications for venture investment of the recent judicial ruling regarding federal funding for stem cell research. Last week’s federal district court ruling ordering an immediate halt in federal funding for stem cell research […]

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

TED DRISCOLL

Ted is an expert on digital health and diagnostics, from big data and health technology to genomics and personalized medicine.

Paul_Straub7765 -1200px

PAUL STRAUB

Paul is particularly focused on the potential of digital and business innovation to impact and advance broad-impact industries.

Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

Post Categories

Archives